Actas urologicas espanolas最新文献

{"title":"Total quantification of circulating microRNAs and smallRNAs in plasma and urine as prognostic biomarkers in prostate cancer.","authors":"M V Lorenzo-Sánchez, M Granada Picazo-Martínez, J M Giménez-Bachs, M J Donate-Moreno, S Navarro Jiménez, M A Tárraga-Honrubia, A S Salinas-Sánchez","doi":"10.1016/j.acuroe.2025.501861","DOIUrl":"https://doi.org/10.1016/j.acuroe.2025.501861","url":null,"abstract":"<p><strong>Introduction: </strong>Circulating RNAs (cfRNAs) have emerged as promising biomarkers in liquid biopsy for prostate cancer (PCa). However, the lack of standardization in their analysis and the heterogeneity across available studies limit clinical application.</p><p><strong>Objective: </strong>To evaluate the diagnostic and prognostic utility of the total concentration of cell-free circulating small RNA (cf-sRNA) and microRNA (cf-miRNA) in plasma and urine from PCa patients using accessible techniques, without identifying specific miRNAs.</p><p><strong>Materials and methods: </strong>Prospective, longitudinal study including 143 men (111 with PCa and 32 healthy controls). Plasma and urine cf-sRNA and cf-miRNA levels were quantified with an Agilent 2100 Bioanalyzer. Levels were correlated with clinical features, tumor stage, and progression to metastatic castration-resistant PCa (mCRPC). A longitudinal follow-up was conducted in a metastatic subgroup.</p><p><strong>Results: </strong>Plasma and urine levels of cf-miRNA and cf-sRNA were significantly higher in patients with advanced PCa, particularly in those who progressed to mCRPC (p < 0.05). During follow-up, a significant increase in plasma cf-miRNA was observed after treatment (p = 0.031), as well as an increase in the relative percentage of cf-miRNA in urine (p = 0.012).</p><p><strong>Results: </strong>Plasma and urine levels of cf-miRNA and cf-sRNA were markedly higher in patients with advanced PCa, particularly in those who progressed to mCRPC (p < 0.05). Plasma cf-miRNA and the relative percentage of cf-miRNA in urine were significantly increased during post-treatment follow-up (p = 0.031 and p = 0.012, respectively).</p><p><strong>Conclusions: </strong>Total quantification of cf-miRNA in plasma and urine is an accessible strategy with potential value as a dynamic biomarker for PCa monitoring and prognosis. Its use could complement current diagnostic tools, although further studies are required to validate its utility in clinical practice.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501861"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific bladder cancer incidence trends and generational effects in Spain.","authors":"L Cayuela, V Achaval, S Cabrera Fernández, M Ortega Calvo, A Cayuela","doi":"10.1016/j.acuroe.2025.501863","DOIUrl":"10.1016/j.acuroe.2025.501863","url":null,"abstract":"<p><strong>Introduction: </strong>This study aimed to assess long-term trends in bladder cancer incidence in Spain from 1992 to 2021, using Age-Period-Cohort (A-P-C) modelling to disentangle the contributions of age, period, and cohort effects.</p><p><strong>Methods: </strong>An ecological trend study was conducted using data from the Global Burden of Disease (GBD) 2021 Study via the Global Health Data Exchange. Age- and sex-specific incidence counts for Spain (1992-2021) were analyzed. Joinpoint regression estimated annual percent changes (APCs) and average annual percent changes (AAPCs). A-P-C modelling assessed net and local drifts, as well as cohort and period rate ratios using 5-year age groups and calendar periods.</p><p><strong>Results: </strong>From 1992 to 2021, 377,430 male and 66,191 female BC cases were estimated. In men, age-adjusted incidence declined (AAPC = -0.6 %), driven by favourable birth cohort and period effects. In women, a modest decline (AAPC = -0.3%) masked a mid-century cohort effect, with increased risk in those born between 1957 and 1967-consistent with a delayed tobacco epidemic. Incidence rose with age in both sexes, though male-to-female incidence ratios narrowed in older groups.</p><p><strong>Conclusion: </strong>BC incidence in Spain reflects complex, sex-specific temporal dynamics. While male incidence is decreasing, women show persistent cohort-specific increases. These trends underscore the importance of sex-sensitive public health strategies targeting modifiable risk factors, particularly tobacco use.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501863"},"PeriodicalIF":0.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of demographic parameters and drainage techniques on the prognosis of emphysematous pyelonephritis: A 10-year single-center retrospective study.","authors":"E Gokmen, M U Kutukoglu, T Altuntas, M Kars, T E Sener, Y Tanidir","doi":"10.1016/j.acuroe.2025.501860","DOIUrl":"10.1016/j.acuroe.2025.501860","url":null,"abstract":"<p><strong>Objective: </strong>To demonstrate the impact of demographic data on the clinical outcomes of patients with emphysematous pyelonephritis (EPN) treated at our center, and to present the results obtained-particularly through the comparison of drainage methods-in the largest patient group possible.</p><p><strong>Materials and methods: </strong>This retrospective single-center study included 54 EPN patients treated at a tertiary care hospital. Inclusion required symptoms of upper urinary tract infection and gas in the renal parenchyma, collecting system, or perinephric space on abdominal CT. Data on demographics, urinary tract stones, labs, imaging (Huang and Tseng classification), hospital and intensive care unit (ICU) stay, and mortality were analyzed by initial treatment, drainage method, and platelet count. Patients with at least 6 months of follow-up were assessed for infection recurrence, renal function loss, and delayed nephrectomy.</p><p><strong>Results: </strong>Advanced age was associated with increased ICU need and mortality (respectively p = 0.047, p = 0.039). Diabetes was associated with longer hospital stays compared to those without DM (14 vs. 7.5 days, p = 0.015). Thrombocytopenia was linked to higher rates of non-functioning kidneys (66.7%) and delayed nephrectomy (33.3%). No significant differences in morbidity or mortality were found between drainage methods (percutaneous vs. DJ stent). More male patients had advanced-stage disease, though this did not impact outcomes.</p><p><strong>Conclusion: </strong>EPN is an emergency urological situation with high rate of mortality. Therefore, early diagnosis and appropriate management are crucial to decrease morbidity and mortality. Patient management approaches can be improved with growing evidence and prospective data with future studies.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501860"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Double J Stent and Major Urological Complications during Extravesical Ureteroneocystostomy in Kidney Transplant Recipients.","authors":"E Venegas-Vázquez, C Beas-Ruiz Velasco, R Martínez de Pinillos-Valverde, J P Gómez-Sierra, C E Capetillo-Texson, V T Hernández-Ramírez, A R Villaseñor-Rodríguez, J M Guzmán-Díaz, X Monteón-Aspeitia, A González-Ojeda, G Cervantes-Guevara, E Cervantes-Pérez, S Ramírez-Ochoa, M G Castillo-Cardiel, C Fuentes-Orozco","doi":"10.1016/j.acuroe.2025.501859","DOIUrl":"10.1016/j.acuroe.2025.501859","url":null,"abstract":"<p><strong>Introduction: </strong>Renal transplantation is the renal replacement therapy of choice in patients with end-stage chronic kidney disease. Major urological complications such as urinary leakage, ureteral stricture and urinary tract infection, usually occur in the first three months post-transplantation and lead to a higher morbidity and mortality and lower graft function.</p><p><strong>Objective: </strong>To evaluate the impact of double J catheter colocation on major urological complications in extravesical ureteroneocystostomy in renal recipients.</p><p><strong>Methods: </strong>Open clinical trial. The study included renal transplant recipients who underwent extravesical ureteroneocystostomy with trans-surgical placement of double J catheter compared to extravesical ureteroneocystostomy without trans-surgical catheter placement. The study variables were urinary leakage, ureteral stricture, urinary tract infection, surgical complications and graft function.</p><p><strong>Results: </strong>84 patients were included, 42 patients in the study group and 42 in the control group, who had a mean follow-up of 10.7 months. Of the urological complications presented: 4 (4.8%) patients with urinary leakage, all in the non-catheter group (RR 0.475 95% CI 0.377-0.598, p = 0.04); 2 (2.4%) patients with ureteral stricture, one in each group (RR 1 95% CI 0. 246-4.066, p = 1.0); and 20 (23.8%) patients with urinary tract infection, being 9 (21.4%) patients in the control group and 11 (26.2%) in the study group (RR 1.135 CI 95% 0.710-1.817, p = 0.608). No differences regarding graft function were observed.</p><p><strong>Conclusion: </strong>Our study showed a significant reduction in the incidence of urinary leakage with prophylactic ureteral catheter use, although no significant association was observed with other complications such as ureteral stricture or surgical complications. Furthermore, its use was not significantly associated with urinary tract infections or graft dysfunction.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501859"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ablative techniques in renal tumours for inoperable patients: Step forward in SBRT.","authors":"A Ocanto, R Ciérvide, V Hevia-Palacios, R García, V Gómez, P Cruz, A Olavarría, F Couñago, F López-Campos","doi":"10.1016/j.acuroe.2025.501857","DOIUrl":"10.1016/j.acuroe.2025.501857","url":null,"abstract":"<p><strong>Introduction: </strong>The localized renal cell carcinoma (RCC) is the eighth most common tumour in Spain. While surgical resection remains the gold standard for treatment, some elderly and frail patients may not be suitable candidates for this procedure. In selected cases, ablative therapies provide less invasive alternatives. Recent research has highlighted the potential of Stereotactic Body Radiotherapy (SBRT) as a non-invasive, well-tolerated, and effective treatment for RCC. This review aims to examine recent advances in SBRT for localized RCC, focusing on patient selection, treatment modalities and delivery, as well as efficacy and tolerance assessment.</p><p><strong>Material and methods: </strong>A narrative literature review of English articles using Pubmed, Scopus, Cochrane, Google Scholar and Science Direct databases was performed focusing on prospective and relevant retrospective studies. Search terms included \"kidney cancer\", \"renal cell carcinoma\", \"stereotactic radiotherapy\", \"radiofrequency ablation\", \"cryoablation\", \"microwave ablation\", \"SBRT\" and \"SABR\".</p><p><strong>Results: </strong>Studies have reported local control rates ranging from 80% to 100% with SBRT. The decline in glomerular filtration rate following SBRT is approximately -10 to -13 mL/min over the years. Common toxicities are rare and are mostly classified as CTCAE grade I.</p><p><strong>Conclusion: </strong>Based on available evidence, SBRT appears to be a viable option for patients with localized RCC who are not surgical candidates, given its high local control rate and favorable safety profile. Therefore, some indications for its use in clinical practice have been purposed according to the available evidence and recommending a case by case discussion in a uro-oncology multidisciplinary setting to optimize patient selection and treatment planning.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501857"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of structured anamnesis for phenotype identification in chronic pelvic pain syndrome: A practice-oriented retrospective study.","authors":"E Vicente Palacio, P Bosch Knape, S Tarragón Gabarro, C Centeno Álvarez, L de Verdonces Román, A Sanchez I Puy, B Juaneda Castell, S Cuadrench Solorzano, E Sotelo Burillo, L M Marco Pérez, L Sabiote Rubio, D Salinas Duffo, J A Peña González","doi":"10.1016/j.acuroe.2025.501858","DOIUrl":"10.1016/j.acuroe.2025.501858","url":null,"abstract":"<p><strong>Objective: </strong>To assess whether chronic pelvic pain presents specific qualitative traits, as described by patients, that can guide identification of its underlying clinical phenotype.</p><p><strong>Materials and methods: </strong>A retrospective study including 157 patients (81 men, 76 women), interviewed systematically by a single evaluator using a structured 10-item table aimed at identifying three possible phenotypes. The correlation between the predicted phenotype (based solely on anamnesis) and the final phenotype (established through physical examination, treatment response, and clinical evolution) was analyzed. Sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were calculated by phenotype and sex. The diagnostic relevance of each question was assessed, and statistical significance was tested using the Chi-square test.</p><p><strong>Results: </strong>In women, the proportion of predicted phenotypes confirmed as final was: 64.5% bladder, 19.7% myofascial, 30.2% neuropathic. In men: 8.6% bladder, 81.5% myofascial, 23.5% neuropathic. Women-bladder: Se 0.92, Sp 0.74, PPV 0.90, NPV 0.72, AUC 0.82. Myofascial: Se 0.44, Sp 0.93, PPV 0.79, NPV 0.75, AUC 0.76. Neuropathic: Se 0.36, Sp 0.98, PPV 0.89, NPV 0.79, AUC 0.51. Men-bladder: Se 0.57, Sp 0.83, PPV 0.21, NPV 0.96, AUC 0.81. Myofascial: Se 0.75, Sp 0.75, PPV 0.93, NPV 0.41, AUC 0.75. Neuropathic: Se 0.29, Sp 1.00, PPV 1.00, NPV 0.80, AUC 0.64.</p><p><strong>Conclusions: </strong>A structured anamnesis may help identify the clinical phenotype underlying chronic pelvic pain (bladder, myofascial, or neuropathic).</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501858"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncological outcomes for patients with European Association of Urology definitions of BCG failure treated with radical cystectomy.","authors":"A Farré, J Huguet, G Basile, L Diéguez, P Izquierdo, R Sánchez, P Gavrilov, A Gallioli, O Rodríguez Faba, J M Gaya, J Palou, A Breda","doi":"10.1016/j.acuroe.2025.501834","DOIUrl":"10.1016/j.acuroe.2025.501834","url":null,"abstract":"<p><strong>Introduction: </strong>The management of non-muscle invasive bladder cancer (NMIBC) failing Bacillus Calmette-Guérin (BCG) therapy remains challenging. The European Association of Urology (EAU) has standardized definitions of BCG failure. We aim to evaluate oncological outcomes in patients undergoing radical cystectomy (RC) for NMIBC following BCG failure, as defined by the EAU.</p><p><strong>Methods: </strong>Retrospective study analyzed 93 patients with NMIBC who underwent RC between 2011 and 2021 after BCG therapy failure. Patients were stratified into 4 groups: clinical NMIBC, clinical progression, subclinical progression (understaged), and pathological NMIBC (pNMIBC) groups. Oncological outcomes included cancer-specific survival (CSS) and overall survival (OS). Kaplan-Meier and logistic regression analyses were used to evaluate outcomes and predictors of disease progression.</p><p><strong>Results: </strong>Among 93 patients, 64 (68.8%) had clinical NMIBC, and 29 (31.2%) showed clinical progression to muscle-invasive bladder cancer (MIBC) prior to RC. Of those with clinical NMIBC, 46 (71.9%) were confirmed as pNMIBC and 18 (28.1%) had subclinical progression. Patients with pNMIBC had significantly better 5-year CSS (95.5%) and OS (77.6%) compared to those with clinical (CSS 70.4%, OS 50.2%) or subclinical progression (CSS 64.1%, OS 43.8%). cT1 with conco-mitant carcinoma in situ and prostatic urethral involvement were independent predictors of muscle-invasive disease at RC.</p><p><strong>Conclusions: </strong>Patients treated at an appropriate stage show superior survival outcomes com-pared to those with progression. These findings underscore the importance of timely surgical intervention in BCG-unresponsive NMIBC and support early RC in select high-risk patients to improve long-term prognosis.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501834"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data from a single-center cohort of patients with metastatic hormone-sensitive prostate cancer in Spain: Analysis of response, progression, and quality of life.","authors":"J García Rodríguez, A López Tello, C González Ruiz de León, R Sacristán González, M Hevia Suárez, J Fuentes Pastor, I Pérez Vera, J M Fernández Gómez","doi":"10.1016/j.acuroe.2025.501838","DOIUrl":"10.1016/j.acuroe.2025.501838","url":null,"abstract":"<p><strong>Introduction: </strong>Real-world analyses reflect routine clinical practice. We reviewed treatment response and quality of life in metastatic hormone-sensitive prostate cancer (mHSPC) patients treated with androgen receptor inhibitors.</p><p><strong>Methods: </strong>We analyzed 89 patients with mHSPC from a descriptive observational cohort. The median follow-up was 16.1 months, with quarterly assessments. We evaluated PSA response, disease progression, and quality-of-life data.</p><p><strong>Results: </strong>Among the patients, 37% had high-volume disease and 63% low-volume; 60% had synchronous metastases. Using apalutamide, we observed PSA reductions of 90%, PSA < 0.2 ng/ml, and ultra-low PSA (<0.02 ng/ml) at 3 and 6 months in 63%, 65%, and 34% and in 65%, 71%, and 53% of patients, respectively. Radiographic progression-free survival (rPFS) was 88% at 15 months. When PET-PSMA was used for imaging, 94% and 92% of patients remained free of radiographic progression at 12 and 24 months, respectively. Regarding quality of life, the FACT-P score remained stable, and pain on the visual analog scale improved, with the proportion of patients scoring >1 decreasing from 35% to 22% over 6 months.</p><p><strong>Conclusion: </strong>Real-world analyses using androgen receptor inhibitors in mHSPC reproduce clinical trial results in terms of treatment response. Profound PSA declines and observed progression-free survival outcomes reflect treatment effectiveness without a negative impact on quality of life.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501838"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of cognitive fusion and standard prostate biopsy after multiparametric prostate magnetic resonance imaging and place of multiparametric prostate magnetic resonance imaging in diagnosis.","authors":"Ö Faruk Akgün, A Altunkol, E Alma, Ü Uysal, B Aksay, Y E Kök","doi":"10.1016/j.acuroe.2025.501839","DOIUrl":"10.1016/j.acuroe.2025.501839","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the diagnostic performance of cognitive fusion biopsy and/or standard systematic biopsy performed following multiparametric magnetic resonance imaging (mpMRI) in the detection of prostate cancer (PCa), and to assess the standalone diagnostic value of mpMRI.</p><p><strong>Materials and methods: </strong>Initially, 1153 patients undergoing PBx from 2017 to 2022 were chosen. Patients were divided into three groups: those with standard PBx without mpMRI (1st group), those with standard PBx after mpMRI (2nd group) and those with standard and cognitive fusion PBx after mpMRI (3rd group). The correlations of general PCa and clinically significant PCa (csPCa) detection rates and Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v2.1) scores were evaluated.</p><p><strong>Results: </strong>The overall PCa detection rate was highest in group 2 (47%). Additionally, the malignancy rate in group 3 was significantly higher compared to group 1 (P < .05). Though the csPCa rate was higher in the third group (40%) compared to the other groups, no significant difference was identified. As the PI-RADS score increased, the malignancy rates appeared to increase. The rate of high-risk patients in the group with cognitive fusion biopsy performed (11, 17%) was higher compared to the second group (P < .05).</p><p><strong>Conclusions: </strong>Multiparametric MRI is valuable in prostate cancer diagnosis, particularly for lesion detection and biopsy guidance in patients with high PI-RADS scores. However, in our study, the addition of cognitive fusion biopsy did not significantly increase the detection rate of csPCa. Further prospective randomized studies are needed to clarify its diagnostic value.</p>","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501839"},"PeriodicalIF":0.0,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145067155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Analysis of device survival and predictive factors in a cohort of patients undergoing male artificial urinary sphincter implantation\". Authors' reply.","authors":"C Minguez Ojeda, A Artiles Medina","doi":"10.1016/j.acuroe.2025.501840","DOIUrl":"10.1016/j.acuroe.2025.501840","url":null,"abstract":"","PeriodicalId":94291,"journal":{"name":"Actas urologicas espanolas","volume":" ","pages":"501840"},"PeriodicalIF":0.0,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}